DE60207824D1 - Cytidin-diphosphocholin gegen diabetische neuropathie - Google Patents

Cytidin-diphosphocholin gegen diabetische neuropathie

Info

Publication number
DE60207824D1
DE60207824D1 DE60207824T DE60207824T DE60207824D1 DE 60207824 D1 DE60207824 D1 DE 60207824D1 DE 60207824 T DE60207824 T DE 60207824T DE 60207824 T DE60207824 T DE 60207824T DE 60207824 D1 DE60207824 D1 DE 60207824D1
Authority
DE
Germany
Prior art keywords
neuropathy
diabetic neuropathy
cytidine
diphosphocholin
against diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60207824T
Other languages
English (en)
Other versions
DE60207824T2 (de
Inventor
Kazuki Endo
Toichi Abiru
Junzo Kamei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamasa Corp
Original Assignee
Yamasa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp filed Critical Yamasa Corp
Publication of DE60207824D1 publication Critical patent/DE60207824D1/de
Application granted granted Critical
Publication of DE60207824T2 publication Critical patent/DE60207824T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60207824T 2001-09-05 2002-09-03 Cytidin-diphosphocholin gegen diabetische neuropathie Expired - Fee Related DE60207824T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001268156 2001-09-05
JP2001268156 2001-09-05
JP2001340838 2001-11-06
JP2001340838 2001-11-06
PCT/JP2002/008916 WO2003022290A1 (fr) 2001-09-05 2002-09-03 Compositions pharmaceutiques pour traiter la neuropathie diabetique

Publications (2)

Publication Number Publication Date
DE60207824D1 true DE60207824D1 (de) 2006-01-12
DE60207824T2 DE60207824T2 (de) 2006-07-06

Family

ID=26621670

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60207824T Expired - Fee Related DE60207824T2 (de) 2001-09-05 2002-09-03 Cytidin-diphosphocholin gegen diabetische neuropathie

Country Status (13)

Country Link
US (2) US6924272B2 (de)
EP (1) EP1362593B1 (de)
JP (1) JP3968347B2 (de)
KR (1) KR100740079B1 (de)
CN (1) CN1551778A (de)
AT (1) ATE311891T1 (de)
CA (1) CA2459469A1 (de)
DE (1) DE60207824T2 (de)
EA (1) EA006776B1 (de)
ES (1) ES2249616T3 (de)
HU (1) HU225988B1 (de)
MX (1) MXPA04002099A (de)
WO (1) WO2003022290A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008179B1 (ru) * 2002-07-11 2007-04-27 Ямаса Корпорейшн Цитидин-5'-дифосфохолин для профилактики или лечения токсической (лекарственно-индуцированной) периферической невропатии
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
DK2343362T4 (da) 2006-07-14 2024-07-08 Patheon Holdings I B V Forbedret fremgangsmåde til dyrkning af celler
KR100812274B1 (ko) * 2006-10-30 2008-03-13 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제
US7836540B2 (en) 2007-08-02 2010-11-23 3M Innovative Properties Company Broom with particle capture sheet
ITMI20121223A1 (it) * 2012-07-13 2014-01-14 Gregorio Fabio De Nuova composizione farmacologica comprendente citicolina in combinazione con glicerolo e/o acetazolamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1188178B (it) * 1985-07-05 1988-01-07 Bioresearch Spa Sali della citidin-difospocolina particolarmente idonei per uso orale
JPH0631306B2 (ja) * 1985-07-12 1994-04-27 武田薬品工業株式会社 シチジン―５′―ジリン酸コリン１水和物結晶の製造法
CA1321994C (en) 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
AU1944799A (en) * 1997-12-24 1999-07-19 Interneuron Pharmaceuticals, Inc. Hyperhydrated citicoline, process and use
JP2000044472A (ja) 1998-07-30 2000-02-15 Kikkoman Corp 糖尿病性合併症の予防または治療薬剤
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases

Also Published As

Publication number Publication date
US20040014711A1 (en) 2004-01-22
CA2459469A1 (en) 2003-03-20
EP1362593B1 (de) 2005-12-07
US20050171051A1 (en) 2005-08-04
ES2249616T3 (es) 2006-04-01
JPWO2003022290A1 (ja) 2004-12-24
EP1362593A1 (de) 2003-11-19
US6924272B2 (en) 2005-08-02
WO2003022290A1 (fr) 2003-03-20
EP1362593A4 (de) 2004-06-30
CN1551778A (zh) 2004-12-01
ATE311891T1 (de) 2005-12-15
MXPA04002099A (es) 2004-06-07
DE60207824T2 (de) 2006-07-06
KR100740079B1 (ko) 2007-07-18
JP3968347B2 (ja) 2007-08-29
HU225988B1 (en) 2008-02-28
HUP0401940A2 (hu) 2005-01-28
US7074773B2 (en) 2006-07-11
EA006776B1 (ru) 2006-04-28
KR20040033002A (ko) 2004-04-17
EA200400394A1 (ru) 2004-08-26

Similar Documents

Publication Publication Date Title
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
EE200300536A (et) Farmatseutiliselt aktiivsed uridiiniestrid
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
EA200601591A1 (ru) Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
PT1040830E (pt) Medicamento para doencas neurodegenerativas
BR0003897A (pt) Aditivo para aumento da resistência à água de formulações cosméticas ou dermatológicas e seus usos
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
BR0012696A (pt) Composição oftálmica
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
BR9910024A (pt) Agente contra resfriado
BR0208727A (pt) Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia
BR0210744A (pt) Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
ATE311891T1 (de) Cytidin-diphosphocholin gegen diabetische neuropathie
SE0004101D0 (sv) New use
BR0313177A (pt) Administração oral de calcitonina
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
BRPI0407271A (pt) Composição anti-helmìntica
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee